Contents

Search

nateglinide (Starlix)

Indications: -> diabetes mellitus type 2 -> control of postprandial hyperglycemia Dosage: 60-120 mg TID before meals Pharmacokinetics: 1) onset of action 15-30 minutes 2) duration of action 2 hours Mechanism of action: 1) stimulates insulin secretion by pancreatic islet beta cells 2) D-phenylalanine derivative Clinical trials: - Navigator study - nateglinide did not reduce the incidence of diabetes or cardiovascular complications [2]

Interactions

drug interactions drug adverse effects of hypoglycemic agents

General

meglitinide (Meglitinido, Meglitinidum)

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 8(2):7 2001 Prescriber's Letter 8(2):supplement 2001
  2. Holman RR for the NAVIGATOR Study Group Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events N Engl J Med. 2010 Mar 29. PMID: 20228402 http://content.nejm.org/cgi/content/full/NEJMoa1001122